fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Breast Cancer & COVID-19 Focused Atossa Therapeutics Receives Another $21M & Presenting Feb.2 At Tribe Public

By John F. Heerdink, Jr.

Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that it has received $21 million from the exercise of outstanding warrants. The warrants were issued in financings in December 2020 and January 2021.

 

 

Kyle Guse, CFO and General Counsel of Atossa Therapeutics (NASDAQ: ATOS)

“In the past 60 days, we have made great progress in adding substantial cash resources so that we can accelerate development of our COVID-19 and breast cancer therapies. We completed financings with gross proceeds of approximately $60 million and in the past week have added an additional $21 million to our balance sheet through the exercise of outstanding warrants. We look forward to the speed at which we can now advance our programs in 2021,” stated Kyle Guse, CFO and General Counsel


Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit: www.atossatherapeutics.com and visit the Atossa Therapeutics Dedicated Page under the VPWatchlist at Vista Partners.


Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D. & CFO, Kyle Guse, Esq., will present at Tribe Public’s Webinar Presentation and Q&A Event titled “The Important Role of COVID Therapeutics in a Post Vaccine World”. The Event is scheduled to begin at 8am Pacific/11am Eastern on Tuesday, February 2, 2021.

To register to join the complimentary, ZOOM webinar-based event, please visit Tribe Public LLC at Atossa2021.TribePublic.com.

Once registered, participants may begin forwarding their questions for Atossa’s management to Tribe Public at research@tribepublic.com or share their questions via the ZOOM chat feature during the event. Tribe Public’s Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.

STEVEN QUAY, M.D., PH.D. BACKGROUND

Steven Quay, M.D., Ph.D. is the founder of Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS). He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital and spent almost a decade on the faculty of Stanford University’s School of Medicine. His contributions to medicine have been cited 9,890 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented. His current passions are solving big medical problems: stopping the COVID-19 pandemic and preventing the two million breast cancer cases in the world each year. A Free copy of Dr. Quay’s best-selling and highly acclaimed book titled “Stay Safe: A Physician’s Guide to the Coronavirus” will be sent to all participants of the Feb. 2, 2021 Tribe Public Event upon request.

Post View Count : 1217
(Read Original Story: Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants in Atossa Therapeutics (NASDAQ: ATOS))


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us